End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphomaJeffrey A. Barnes, Jeremy S. Abramson, Ann S. LaCasce et al.|Annals of Oncology|2010Cited by 105
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaJeffrey A. Barnes, Jeremy S. Abramson|Haematologica|2012Cited by 67
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S. Topp, Jennifer L. Crombie, Jean‐Marie Michot et al.|Blood|2024Cited by 28
Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 StudyJennifer L. Crombie, Steve M Ansell, Matthew J. Matasar et al.|Blood|2023Cited by 8
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP. Connor Johnson, Areej El‐Jawahri, Jeremy S. Abramson et al.|Journal of the National Comprehensive Cancer Network|2025Cited by 4